The market for HPAPIs is growing due to the increasing prevalence of complex diseases like cancers, autoimmune disorders, infectious diseases and rare diseases. Indena is at the forefront in addressing the last market challenges, as its capability in HPAPIs production comes from the experience done more than 30 years ago with the first oncological blockbuster drug, Paclitaxel. In fact, one of the main topic Indena will cover at CPhI this year are ADCs. Indena’s ambitions is to extend its expertise also to Antibody drug conjugates being able to manufacture linker-payload.
Of course, Indena’s goal continues to be offering its customers the possibility of carrying out synthetic processes in a wide range of conditions, both for naturally derived molecules (from botanical sources or from microbial fermentation) requiring semisynthetic steps and for total-synthetic molecules. To allow the company to produce and commercialize many more regular APIs and HPAPIs, a new industrial GMP line with reactors until 10 000L is being implemented.
Indena will present also new products: resiniferatoxin for clinical use, from the sustainable supply chain of Euphorbia resinifera O. Berg; squalene of vegetable origin, to be used as vaccine coadjuvant, extracted from Amaranthus sp.; and cytisine, used as antismoking agent, produced using plants of Laburnum anagyroides Medik with a defined origin, a controlled certified and fully traced biomass supply chain.
To know more and meet our sales and technical staff, visit Indena at CPhI 2024: Hall 4, Booth C9 – 8th – 10th October 2024 – Fiera Milano, Italy
